MAGEA8: A Potential Drug Target and Biomarker (G4107)

Target Name: MAGEA8

NCBI ID: G4107

MAGEA8

MAGEA8: A Potential Drug Target and Biomarker

MAGEA8, a member of the MAGE family, is a cytoskeleton-associated protein that plays a crucial role in cell signaling and structure. MAGEA8 has been identified as a potential drug target and biomarker due to its unique structure, biology, and function in various cellular processes.

Structure and Function

MAGEA8 is a 21-kDa protein that consists of a unique N-terminal domain, a transmembrane region, and an C-terminal domain. The N-terminal domain is rich in amino acids that are involved in the formation of a hydrogen-bonded network with other cytoskeleton proteins. This network is known as the MAGEA8-associated protein complex (MAPC) and is involved in regulating various cellular processes, including cell signaling, cytoskeleton organization, and cell-cell adhesion.

The transmembrane region of MAGEA8 is characterized by a unique arrangement of 12 conserved transmembrane domains, each of which is involved in the regulation of various cellular processes. This region is also involved in the formation of MAPC and is critical for the stability and localization of MAGEA8.

The C-terminal domain of MAGEA8 is responsible for the protein's unique stability and localization in the cytoskeleton. This domain is rich in amino acids that are involved in the formation of a stable interaction between MAGEA8 and microtubules, the protein network that pulls the cell's cytoskeleton in torsional tension. This interaction between MAGEA8 and microtubules is critical for the regulation of cell signaling and cytoskeleton organization.

MAGEA8 Functions

MAGEA8 plays a crucial role in regulating various cellular processes, including cell signaling, cytoskeleton organization, and cell-cell adhesion. One of the most well-studied functions of MAGEA8 is its role in regulating the formation and stability of microtubules in the cytoskeleton. MAGEA8 is known to interact with the protein tau and is involved in the regulation of tau tangles, which are a hallmark of neurodegenerative diseases.

In addition to its role in regulating microtubules, MAGEA8 is also involved in the regulation of actinin, a protein that plays a critical role in cell-cell adhesion. MAGEA8 has been shown to interact with actinin and is involved in the regulation of actinin-associated protein (AAP) complex, which is involved in the regulation of cell-cell adhesion.

MAGEA8 is also involved in the regulation of cell signaling, including the regulation of the cytoskeleton-associated protein (CAP) kinase. This protein is involved in the regulation of various cellular processes, including cell signaling, cytoskeleton organization, and cell-cell adhesion. MAGEA8 has been shown to interact with CAP and is involved in the regulation of CAP activity.

MAGEA8 Interactions

MAGEA8 has been shown to interact with a variety of proteins, including tau, actinin, and CAP. These interactions are critical for the regulation of various cellular processes, including cell signaling, cytoskeleton organization, and cell-cell adhesion.

MAGEA8 Interactions with Tau

Tau is a protein that is involved in the regulation of various cellular processes, including the regulation of cell signaling and the formation of tangles, which are a hallmark of neurodegenerative diseases. MAGEA8 has been shown to interact with tau and is involved in the regulation of tau tangles. This interaction between MAGEA8 and tau is critical for the regulation of

Protein Name: MAGE Family Member A8

Functions: Not known, though may play a role in embryonal development and tumor transformation or aspects of tumor progression

The "MAGEA8 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about MAGEA8 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets